MX2019007574A - Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. - Google Patents

Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.

Info

Publication number
MX2019007574A
MX2019007574A MX2019007574A MX2019007574A MX2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A
Authority
MX
Mexico
Prior art keywords
linaclotide
delayed release
modified
methods
release formulations
Prior art date
Application number
MX2019007574A
Other languages
Spanish (es)
Inventor
Hashash Ahmad
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MX2019007574A publication Critical patent/MX2019007574A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods for treating a patient with a disorder, such as a GI disorder or symptoms associated with a GI or non-GI disorder, by administering a therapeutically effective amount of a delayed release pharmaceutical composition comprising linaclotide.
MX2019007574A 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. MX2019007574A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437566P 2016-12-21 2016-12-21
PCT/US2017/067814 WO2018119191A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Publications (1)

Publication Number Publication Date
MX2019007574A true MX2019007574A (en) 2019-09-04

Family

ID=61022424

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007574A MX2019007574A (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.
MX2023008839A MX2023008839A (en) 2016-12-21 2019-06-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008839A MX2023008839A (en) 2016-12-21 2019-06-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.

Country Status (10)

Country Link
EP (1) EP3558337A1 (en)
JP (2) JP2020512292A (en)
CN (1) CN110475564A (en)
AU (1) AU2017379082A1 (en)
BR (1) BR112019012689A2 (en)
CA (1) CA3048195A1 (en)
EA (1) EA201991531A1 (en)
MA (1) MA47112A (en)
MX (2) MX2019007574A (en)
WO (1) WO2018119191A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979992A4 (en) * 2019-06-10 2023-09-13 Ironwood Pharmaceuticals, Inc. Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome
IL313184A (en) * 2021-11-29 2024-07-01 Ironwood Pharmaceuticals Inc Pharmaceutical compositions for the treatment of visceral pain
WO2023196821A2 (en) * 2022-04-04 2023-10-12 Thomas Jefferson University Targeting neuropod cell gucy2c to control visceral pain and appetite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL2328601T3 (en) 2008-08-15 2020-07-13 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011020054A1 (en) * 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
UA108636C2 (en) 2010-02-17 2015-05-25 PEPTIDE
SI2603232T1 (en) * 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
JP6312592B2 (en) * 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド Treatment of digestive disorders
WO2014113377A1 (en) * 2013-01-15 2014-07-24 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
UA119335C2 (en) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Delayed release compositions of linaclotide
JP2018516937A (en) * 2015-06-05 2018-06-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド Modified or targeted release formulation of linaclotide

Also Published As

Publication number Publication date
BR112019012689A2 (en) 2019-11-19
AU2017379082A1 (en) 2019-07-04
JP2020512292A (en) 2020-04-23
CN110475564A (en) 2019-11-19
EP3558337A1 (en) 2019-10-30
MX2023008839A (en) 2023-08-14
WO2018119191A1 (en) 2018-06-28
CA3048195A1 (en) 2018-06-28
MA47112A (en) 2019-10-30
EA201991531A1 (en) 2019-11-29
JP2022093472A (en) 2022-06-23
WO2018119191A9 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2023010042A (en) Modulatory polynucleotides.
MX2023008686A (en) Modulatory polynucleotides.
MX2018005340A (en) Proteolysis targeting chimera compounds and methods of preparing and using same.
EA201890051A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891199A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EA201890048A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890047A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
GB2541571A (en) Pharmaceutical compositions
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA036102B9 (en) Glycotargeting therapeutics
EA201791875A1 (en) COMBINED COMPOSITION OF THESOPHENZINE AND BETA BLOCKER
MX2023008839A (en) Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.
MX2018002446A (en) Fused heterocyclic compounds as s1p modulators.
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
NZ737410A (en) Compositions comprising anakinra
MX2017002277A (en) Factor h potentiating antibodies and uses thereof.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
JO3621B1 (en) Compounds And Compositions As Toll-Like Receptor 7 Agonists